Common Contracts
2 similar Co-Exclusive License Agreement contracts by Alnylam Pharmaceuticals, Inc.
ContractCo-Exclusive License Agreement • May 5th, 2020 • Massachusetts
EX-10.4 5 b85475exv10w4.htm EX-10.4 Exhibit 10.4 AMENDMENT TO CO-EXCLUSIVE LICENSE AGREEMENT This Amendment to the Alnylam Co-Exclusive License Agreement is made as of March 14, 2011 (“Effective Date”), by and between Alnylam Pharmaceuticals, Inc. (“Alnylam”), on the one hand, and Whitehead Institute for Biomedical Research (“Whitehead”), Massachusetts Institute of Technology (“MIT”), and Max-Planck-Innovation GmbH (“MI”). This agreement is made with respect to the following recitals: WHEREAS, Alnylam and MI (at the time called Garching Innovation GmbH and referred to as GI in the Alnylam Co-Exclusive License Agreement) are parties to the Alnylam Co-Exclusive License Agreement; WHEREAS, Whitehead and MIT joined the Alnylam Co-Exclusive License Agreement on July 30, 2003; WHEREAS, the Alnylam Co-Exclusive License Agreement grants, among other things, a license to the “MAX PLANCK PATENT RIGHTS” (as that term is defined in the Alnylam Co-Exclusive License Agreement) to Alnylam, subject to
AMENDMENT TO CO-EXCLUSIVE LICENSE AGREEMENTCo-Exclusive License Agreement • May 5th, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to the Alnylam Co-Exclusive License Agreement is made as of March 14, 2011 (“Effective Date”), by and between Alnylam Pharmaceuticals, Inc. (“Alnylam”), on the one hand, and Whitehead Institute for Biomedical Research (“Whitehead”), Massachusetts Institute of Technology (“MIT”), and Max-Planck-Innovation GmbH (“MI”).
